Literature DB >> 31332668

Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients.

Roger K Verbeeck1, Bonifasius S Singu2, Dan Kibuule2.   

Abstract

Entities:  

Year:  2019        PMID： 31332668     DOI： 10.1007/s40262-019-00800-1

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  39 in total

Review 1.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  Maturational changes in vancomycin protein binding affect vancomycin dosing in neonates.

Authors:  Stéphanie Leroux; Johannes N van den Anker; Anne Smits; Marc Pfister; Karel Allegaert
Journal:  Br J Clin Pharmacol       Date:  2019-03-04       Impact factor: 4.335

4.  Binding of rifampicin by human plasma proteins.

Authors:  G Boman; V A Ringberger
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

5.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration.

Authors:  U Loos; E Musch; J C Jensen; G Mikus; H K Schwabe; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-12-02

Review 6.  Plasma protein binding: from discovery to development.

Authors:  Tonika Bohnert; Liang-Shang Gan
Journal:  J Pharm Sci       Date:  2013-06-24       Impact factor: 3.534

7.  Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

Authors:  Sekai Chideya; Carla A Winston; Charles A Peloquin; William Z Bradford; Philip C Hopewell; Charles D Wells; Arthur L Reingold; Thomas A Kenyon; Themba L Moeti; Jordan W Tappero
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

8.  Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Authors:  A Bekker; H S Schaaf; H R Draper; L van der Laan; S Murray; L Wiesner; P R Donald; H M McIlleron; A C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

9.  Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.

Authors:  K E Stott; H Pertinez; M G G Sturkenboom; M J Boeree; R Aarnoutse; G Ramachandran; A Requena-Méndez; C Peloquin; C F N Koegelenberg; J W C Alffenaar; R Ruslami; A Tostmann; S Swaminathan; H McIlleron; G Davies
Journal:  J Antimicrob Chemother       Date:  2018-09-01       Impact factor: 5.790

10.  A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

Authors:  Alper Daskapan; Lusiana R Idrus; Maarten J Postma; Bob Wilffert; Jos G W Kosterink; Ymkje Stienstra; Daniel J Touw; Aase B Andersen; Adrie Bekker; Paolo Denti; Agibothu K Hemanth Kumar; Kidola Jeremiah; Awewura Kwara; Helen McIlleron; Graeme Meintjes; Joep J van Oosterhout; Geetha Ramachandran; Neesha Rockwood; Robert J Wilkinson; Tjip S van der Werf; Jan-Willem C Alffenaar
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447
View more
  2 in total

1.  A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats.

Authors:  Priyanka Kulkarni; Ken Korzekwa; Swati Nagar
Journal:  Xenobiotica       Date:  2019-10-01       Impact factor: 1.908

2.  Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.

Authors:  Jesper Sundell; Emile Bienvenu; Angela Äbelö; Michael Ashton
Journal:  J Antimicrob Chemother       Date:  2021-10-11       Impact factor: 5.790
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.